Comparison Overview

MENARINI Group

VS

Dr. Reddy's Laboratories

MENARINI Group

Via dei Sette Santi 1/3, Firenze, Italy, IT, 50131
Last Update: 2025-12-09
View Profile
Between 750 and 799
https://www.menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,572
Subsidiaries: 26
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TS, IN, 500034
Last Update: 2025-12-09
Between 750 and 799
http://www.drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com.  Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages.  Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 30,765
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MENARINI Group
100%
Compliance Rate
0/4 Standards Verified
Dr. Reddy's Laboratories
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MENARINI Group in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2025.

Incident History — MENARINI Group (X = Date, Y = Severity)

MENARINI Group cyber incidents detection timeline including parent company and subsidiaries

Incident History — Dr. Reddy's Laboratories (X = Date, Y = Severity)

Dr. Reddy's Laboratories cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
Incidents

No Incident

https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
Incidents

No Incident

FAQ

Dr. Reddy's Laboratories company demonstrates a stronger AI Cybersecurity Score compared to MENARINI Group company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Dr. Reddy's Laboratories company has disclosed a higher number of cyber incidents compared to MENARINI Group company.

In the current year, Dr. Reddy's Laboratories company and MENARINI Group company have not reported any cyber incidents.

Neither Dr. Reddy's Laboratories company nor MENARINI Group company has reported experiencing a ransomware attack publicly.

Neither Dr. Reddy's Laboratories company nor MENARINI Group company has reported experiencing a data breach publicly.

Neither Dr. Reddy's Laboratories company nor MENARINI Group company has reported experiencing targeted cyberattacks publicly.

Neither MENARINI Group company nor Dr. Reddy's Laboratories company has reported experiencing or disclosing vulnerabilities publicly.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds any compliance certifications.

Neither company holds any compliance certifications.

MENARINI Group company has more subsidiaries worldwide compared to Dr. Reddy's Laboratories company.

Dr. Reddy's Laboratories company employs more people globally than MENARINI Group company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds SOC 2 Type 1 certification.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds SOC 2 Type 2 certification.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds ISO 27001 certification.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds PCI DSS certification.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds HIPAA certification.

Neither MENARINI Group nor Dr. Reddy's Laboratories holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References